You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. Comfortable, Easy-To-Fit, Deep-Insert Earplug

    SBC: PAXAURIS LLC            Topic: DHA19C001

    Effective hearing protection is essential for service members who work in hazardous noise environments and for whom permanent or even temporary hearing damage affects performance, endangers lives, and reduces quality of life. Various devices have been developed to attenuate high levels of impulse and continuous noise while allowing low-level sounds to pass through. However, issues with comfort, ea ...

    STTR Phase I 2020 Department of DefenseDefense Health Agency
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. POC Blood Coagulopathy Monitor

    SBC: CFD Research Corporation            Topic: DHA19A001

    Traumatic injuries account for 30% of all life years lost in the US and is the leading cause of death for people under 46 years of age. Uncontrolled bleeding or hemorrhage constitute 30-40% of trauma related deaths and are considered to be a major cause o

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  6. Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

    SBC: Innosense Llc            Topic: DHA19A001

    Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  7. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GeneCapture, Inc.            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  8. High Fidelity Computational Models for Aggregated Tissue Interaction in Surgical Simulations

    SBC: CFD Research Corporation            Topic: DHP16A001

    Surgical simulations aiming to support surgeon practices and medical education have attracted enormous research effort over the last two decades. However, the physical reality, especially on simulating aggregated tissue interaction, is still unsatisfactory. In this proposed work, an open source surgery simulation framework, SoFMIS, will be utilized and enhanced with tissue interaction models to a ...

    STTR Phase I 2016 Department of DefenseDefense Health Agency
  9. Use of Highly Porous Polymer Beads to Remove Anti-A and Anti-B Antibodies from Plasma for Transfusion

    SBC: CYTOSORBENTS MEDICAL INC            Topic: DHP15B001

    The ready availability of universal donor plasma to rapidly treat massively bleeding hospital trauma patients and warfighters with combat casualties is a key element of current recommendations for trauma resuscitation, yet universal AB donor plasma is rel

    STTR Phase I 2016 Department of DefenseDefense Health Agency
  10. Innovative Wound Regeneration Support Approaches to Enable Rapid Treatment of Wounded Warfighters

    SBC: Zetroz Systems LLC            Topic: A14AT016

    Ultrasound is a therapeutic modality which has been used clinically for 60 years, but has been limited in practice by the complexity of the technology. Recent research has allowed for the development of a portable, wearable, long duration, low intensity therapeutic ultrasound system. The system is powered by battery, and can be applied by a user to deliver up

    STTR Phase II 2016 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government